Digital therapeutics (DTx) startup Sidekicks has raised USD 55 million (EUR 52 million) in a Series B funding round led by London-based Novator Ventures, with participation from Wellington Partners, Asabys Partners, and Frumtak Ventures, and a US-based strategic investor.
The funds will be used to expand its chronic disease treatment programs into new therapeutic areas, as well as to form new partnerships and enhance existing ones with players in the healthcare and pharmaceutical industry. Additionally, the company plans to double its headcount to 240 team members.
The B2B2C DTx company is focused on developing personalized programs for patients with chronic conditions - from cancer to heart health - and other behavioral conditions such as smoking addiction. Its platform offers gamified content that incorporates lifestyle changes and clinical treatments to improve healthcare outcomes. The firm partners with health plans such as Anthem to reach patients and develops DTx solutions with pharma giants including Pfizer and Bayer. It has served over 40,000 patients globally across the US, Germany, Sweden, and Iceland.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.